Semaglutide Studies Show More Than Personal Reports Can Prove

Studies found stomach trouble; people noticed other changes

Nausea, diarrhea, constipation, and vomiting were the most common problems in studies, so you’re likely to hear about them first. Researchers also warned about less common harm to the thyroid, pancreas, gallbladder, eyes, and muscle. Weight often came back after treatment ended, which means the studies didn’t show a lasting cure.

People also describe less hunger, weight loss, foul burps, tiredness, and hair shedding. These accounts show what a person noticed, but can’t prove that Semaglutide caused the change. No dose or care plan appears on this page; your doctor can help with those choices.

People describe possible help and possible discomfort

The reports below are from people using Semaglutide for research. They weren’t gathered by comparing one group with a second, and no formal study has checked the claims. The accounts show what others felt, not what you will feel, and they include no doses.

Changes some people welcome

• Fewer thoughts about meals. Many say thoughts of food no longer fill the whole day. They feel satisfied sooner and leave more behind. This account is common.
• Fewer cravings. Some people say sweets and greasy meals seem less tempting, while others find lighter food easier to choose. That report appears often.
• Lower weight. Many accounts describe a steady drop over several months, though the pace often slows later. People usually tie the change to smaller meals, not more exercise.
• Steadier readings. Those with type 2 diabetes often mention lower blood sugar and A1C blood-test results. Some say the readings returned to their usual range, but these remain personal accounts.
• Less interest in alcohol. As food cravings ease, some people also want fewer drinks. A few say alcohol no longer appeals at all, though this report is less common.

Discomfort people often describe

• Nausea and vomiting. Roughly one out of three reviewers brings up nausea, often at first or when researchers raise the amount. Rich meals and overeating may make it worse.
• Foul burps. Some burps have an egg-like smell, along with bloating and a sense that food is moving slowly. The problem may last hours or even weeks.
• Constipation or diarrhea. Some people can’t move their bowels easily, while others have loose stools. A few swing between the problems, and rich meals may worsen either one.
• Heartburn. Some people feel chest burning or acid rising into the throat, sometimes with burping and bloating. More burning may follow an increase in the amount.
• Tiredness. A shot may be followed by low energy, or the feeling may appear near the start. Many say their strength returns later, but a personal report can’t prove cause.
• Changed taste or smell. Some people find meat, grease, or strong smells hard to bear. Others get a metal taste, and a few lose enough interest to forget a meal.
• Hair or face changes. A smaller group sees more hair in the brush after several months. They often link hair and face changes to fast weight loss, and most describe the shedding as brief.
• Headache or dizziness. These problems may appear when the amount changes. Some people blame a lack of food or water, though that cause hasn’t been proved.
• Shot-site soreness. The skin may turn red, itch, hurt, or form a small bump where the shot went in. People usually describe the problem as mild and say it clears soon.

The full safety list explains what is known about each risk

These cautions come from clinical trials, drug labels, and pharmacovigilance (the formal monitoring of side effects after a drug is on the market). Each is cited. Where a concern is theoretical or extrapolated rather than a proven clinical finding, it says so.

The stomach is the main event. Nausea, vomiting, diarrhea, and constipation are the dominant adverse effects in the trials and the leading reason people stop. In the pooled STEP weight-management analysis these were mostly mild-to-moderate and transient, clustered around the dose-escalation period, and a dedicated safety review put nausea at roughly one-third of patients ^[5]. This is mechanism, not bad luck: slowing the stomach's emptying is part of how the drug works ^[4][5].

Thyroid boxed warning (history of medullary thyroid carcinoma or MEN-2). GLP-1 receptor agonists carry a boxed warning for thyroid C-cell tumors, drawn from rodents given very high exposures ^[6][5]. A dedicated assessment of thyroid cancer risk concluded that human data do not establish a clear increase attributable to semaglutide — so the human signal is unconfirmed — yet a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 is treated as a contraindication on the strength of the animal finding ^[6][5].

Pancreatitis (class warning). Acute pancreatitis is a recognized class warning, and treatment is conventionally stopped if it is suspected ^[5]. Pancreatic-cancer signals remain ones for which firm conclusions cannot yet be drawn because of low numbers, not confirmed associations ^[5]. The caution is precautionary, not a demonstrated risk increase.

Gallbladder disease. A dedicated safety review found increased biliary disease (gallstones) versus placebo ^[5]. It is attributed largely to the rate and amount of weight loss rather than direct drug toxicity — but the increase is a real trial and monitoring finding, not just theory ^[5].

Eyes, in people with diabetes correcting blood sugar fast. In SUSTAIN-6, diabetic-retinopathy complications were significantly more frequent on semaglutide (HR 1.76; 95% CI 1.11-2.78), concentrated in people with pre-existing retinopathy whose blood sugar dropped rapidly ^[2][5]. The leading read is early worsening driven by the speed of correction, not direct retinal toxicity; monitoring is advised when glucose is corrected quickly ^[2][5].

Muscle loss. A STEP-program DXA body-composition substudy found the weight lost included both fat and a meaningful share of lean (muscle) mass ^[11]. Because fast, large weight loss can erode muscle, this raises a sarcopenia concern, especially in older adults, and has driven research into protein intake and resistance training. The lean-mass loss is observed; the downstream muscle-frailty risk is a reasoned extrapolation ^[11].

Weight regain after stopping. Stopping is followed by substantial regain. In the STEP 1 extension, people regained a mean of roughly 11.6 percentage points within a year and cardiometabolic gains reverted toward baseline; the STEP 4 withdrawal design showed the same after switching to placebo ^[19][14]. This frames it as a chronic, not curative, intervention.

Hair shedding. A pharmacovigilance disproportionality analysis flagged an alopecia reporting signal with semaglutide and tirzepatide, and a separate dermatology study tied telogen effluvium (reversible diffuse shedding) to the size and speed of weight loss ^[15][16]. The signal fits weight-loss-driven shedding rather than direct drug toxicity.

Pregnancy. Contraindicated per the label. Because the half-life is about a week — effectively cleared only about five weeks after the last dose — guidance advises stopping well before a planned pregnancy, commonly cited as roughly two months ^[17]. The washout math is documented; the contraindication itself is a regulatory statement.

The oral tablet is fussy. Oral semaglutide is co-formulated with the absorption enhancer SNAC and has very low oral bioavailability (~0.4-1%), so it must be taken on an empty stomach with only a little water and kept apart from other food, drink, and medicine — getting that wrong can substantially cut the absorbed dose ^[12][17]. That is a formulation requirement, not a toxicity.

Drug interactions are mostly mild. A systematic review found the delayed stomach emptying generally does not cause clinically significant interactions, but advised monitoring narrow-therapeutic-index oral drugs during dose escalation ^[18]. Overall interaction risk is characterized as low.

None of the above is a dosing instruction, and none of it is medical advice — it is cited context.

A safety page can map the evidence; it cannot clear an individual to use Semaglutide, which belongs in prescription-only care through a licensed, clinician-led route such as Promise Peptides (mypromise.com).

Semaglutide gained more uses before shortage rules tightened

Semaglutide was built to last longer while copying GLP-1, a gut hormone ^[12]. It also resists DPP-4, a substance that would break the medicine down too soon. The medicine was cleared for type 2 diabetes in 2017, followed by a tablet in 2019-2020. Weight care followed in 2021, with heart-risk care later. In 2025, use widened to a serious liver disease caused by fat buildup and scarring ^[3][12].

The shortage lasted from about 2022 into early 2025, when special rules let some pharmacies mix their own Semaglutide. Officials said the shortage ended in 2025. Much of that temporary permission then ended, leaving fewer pharmacies able to make their own version.